Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18681136 | 0.87 | ACE (0.42) | ACEDPP4DPP8DPP7PREP | |
| SCHEMBL8278480 | 0.82 | ACE (0.47) | ACEDPP4DPP8DPP7PREP | |
| SCHEMBL18675236 | 0.78 | PREP (0.41) | ACEDPP4DPP8PREPFAP | |
| SCHEMBL17282590 | 0.75 | ACE (0.43) | ACEDPP4DPP8DPP7PREP | |
| SCHEMBL18675240 | 0.75 | PREP (0.49) | ACEDPP4DPP8PREPFAP | |
| SCHEMBL18675250 | 0.74 | PREP (0.45) | ACEPREPFAPHSD17B10KDM4E | |
| SCHEMBL18675241 | 0.74 | ATM (0.44) | DPP4DPP8DPP7PREPFAP | |
| SCHEMBL18675242 | 0.74 | ATM (0.44) | DPP4DPP8DPP7PREPFAP | |
| SCHEMBL18675244 | 0.73 | PSMB9 (0.35) | DPP4DPP8DPP7PREPFAP | |
| SCHEMBL18675243 | 0.73 | PIN1 (0.42) | DPP4DPP8DPP7PREPFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | ACE 170/4885DPP4 58/4885DPP8 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.